Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Dow
Moodys
Mallinckrodt

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Anamorelin

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Anamorelin?

Anamorelin is an investigational drug.

There have been 10 clinical trials for Anamorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Cachexia. The leading clinical trial sponsors are Helsinn Therapeutics (U.S.), Inc, Helsinn Healthcare SA, and M.D. Anderson Cancer Center.

There are seventeen US patents protecting this investigational drug and two hundred and twenty-two international patents.

Recent Clinical Trials for Anamorelin
TitleSponsorPhase
Effect of a Ghrelin Receptor Agonist on Muscle and BoneNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Phase 1
Effect of a Ghrelin Receptor Agonist on Muscle and BoneTufts UniversityPhase 1
Anamorelin Hydrochloride in Reducing Anorexia in Participants With Advanced Non-small Cell Lung CancerNational Cancer Institute (NCI)Phase 2/Phase 3

See all Anamorelin clinical trials

Clinical Trial Summary for Anamorelin

Top disease conditions for Anamorelin
Top clinical trial sponsors for Anamorelin

See all Anamorelin clinical trials

US Patents for Anamorelin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Anamorelin   Start Trial Methods of producing anamorelin hydrochloride having controlled chloride content ONO PHARMACEUTICAL CO., LTD (Osaka, JP) HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH)   Start Trial
Anamorelin   Start Trial Compound with growth hormone releasing properties Novo Nordisk A/S (Bagsvaerd, DK)   Start Trial
Anamorelin   Start Trial Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxy- lic acid 1,2,2-trimethylhydrazide Helsinn Therapeutics (U.S.), Inc. (Bridgewater, NJ)   Start Trial
Anamorelin   Start Trial Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues Helsinn Therapeutics (U.S.), Inc. (Bridgewater, NJ)   Start Trial
Anamorelin   Start Trial Methods of treating emesis using growth hormone secretagogues Helsinn Therapeutics (U.S.), Inc. (Bridgewater, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Anamorelin

Drugname Country Document Number Estimated Expiration Related US Patent
Anamorelin Argentina 090725 2032-04-20   Start Trial
Anamorelin Australia 2013249197 2032-04-20   Start Trial
Anamorelin Brazil 112014025972 2032-04-20   Start Trial
Anamorelin Canada 2869893 2032-04-20   Start Trial
Anamorelin Canada 3031652 2032-04-20   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Express Scripts
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.